Investment Securities

6 Months Ended

Jan. 31, 2020

Notes to Financial Statements

Investment Securities

NOTE 8. INVESTMENT SECURITIES

On July 31, 2019 the Company recognized 66,667 of the common shares of Entest Group, Inc. acquired in the reverse merger.

On July 31, 2019 the Company recognized 29,076,665 of the common shares of Regen Biopharma, Inc. acquired in the reverse merger.

On July 31, 2019 the Company recognized 2,907,665 of the Series A Preferred shares of Regen Biopharma, Inc. acquired in the reverse merger.

On July 31, 2019 the Company recognized 4,411 of the common shares of Zander Therapeutics, Inc. acquired in the reverse merger.

On July 31, 2019 the Company recognized 5,000 of the Series M Preferred Shares of Zander acquired in the reverse merger

On July 31, 2019 the Company recognized 8,333 of the Preferred Series B shares of of Entest Group, Inc. acquired in the reverse merger.

As of January 31, 2019

66,667 Common Shares of Entest Group, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January  31 2020		Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	1,133	$	480	$	(946)	$	(652)

29,076,665 Common Shares of Regen Biopharma, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January 31, 2020		Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	17,446	$	2,907	$	(20,353)	$	(14,538)

290,766 Series A Preferred Shares of Regen Biopharma,  Inc.
	Basis	Fair Value		Change in Fair Value for the Quarter ended January 31 2020		Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	29,076	9,595	$	1,454	$	(19,480	)

4,411 Common Shares of Zander Therapeutics, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January 31 2020			Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	254	$	0	$	(71	)	$	(254	)

5,000 Series M Preferred Shares of Zander Therapeutics, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January 31, 2020			Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	289	$	0	$	(80	)	$	(289	)

8,333 Series B Preferred Shares of Entest Group, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January 31 2020		Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	0	$	0	$	0	$	0